$4.82
Value $381M
CRMD and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$4.82
Value $381M
$691.33
Value $257B
CorMedix (CRMD) has a market value of $381M and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, CRMD moved -57.1% and TMO +19.9%. The P/E is 6.0 for CRMD and 36.3 for TMO. Dividend yield: CRMD none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CRMD$381M
TMO$257B
TMO is 674 times CRMD
Revenue, 12 months
CRMD$412M
TMO$47.4B
TMO is 115 times CRMD
Net income, 12 months
CRMD$64M
TMO$7.1B
TMO is 111 times CRMD
Operating margin
CRMD38.6%
TMO17.9%
20.7 points apart
ROIC
CRMD27.3%
TMO8.2%
19.1 points apart
P/E
CRMD6.0
TMO36.3
TMO is 6.1 times CRMD
Dividend yield
CRMD0.0%
TMO0.3%
0.3 points apart
5-year return
CRMD-7.3%
TMO+10.9%
18.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CRMD-7.3%
TMO+10.9%
| Period | CRMDWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | -57.1%Price -57.1% | +19.9%Price +19.5% |
| 3 years since November 16, 2023 | +26.8%+8.2% a yearPrice +26.8% | +47.7%+13.9% a yearPrice +46.3% |
| 5 years since November 15, 2021 | -7.3%-1.5% a yearPrice -7.3% | +10.9%+2.1% a yearPrice +9.3% |
| 10 years since November 16, 2016 | -43.6%-5.6% a yearPrice -43.6% | +375.7%+16.9% a yearPrice +362.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CRMDCorMedixTMOThermo Fisher Scientific
| Price | $4.82 | $691.33 |
|---|---|---|
| Market value | $381M | $257B |
| Enterprise value (EV) | $26M | $292B |
| P/E | 6.0 | 36.3 |
| P/E, 5-year median | – | 32.7 |
| P/B | 0.8 | 4.7 |
| EV/EBIT | 0.2 | 34.5 |
| Free cash flow yield | 80.8% | 3.0% |
| Revenue, 12 months | $412M | $47.4B |
|---|---|---|
| Net income, 12 months | $64M | $7.1B |
| Free cash flow, 12 months | $308M | $7.6B |
| Earnings per share, 12 months | $0.81 | $18.96 |
| Revenue growth, year on year | 617.0% | 3.9% |
| Revenue growth a year, past | +319.8%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | 77.5% | – |
|---|---|---|
| Operating margin | 38.6% | 17.9% |
| Net margin | 15.5% | 14.9% |
| ROIC | 27.3% | 8.2% |
| ROE | 14.9% | 13.4% |
| Cash | $355M | $6.1B |
|---|---|---|
| Total debt | $144.6K | $41.4B |
| Net debt / EBITDA | -2.2 | 3.7 |
| Interest cover | 57.2× | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($257B) is about 674.0 times CorMedix ($381M), at today's prices.
Since November 16, 2016, CRMD's price moved -43.6% and TMO's +362.5%. With dividends: CRMD -43.6% (-5.6% a year), TMO +375.7% (+16.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for CorMedix and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
At today's price, the P/E is 6.0 for CRMD and 36.3 for TMO. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 15.5% for CorMedix and 14.9% for Thermo Fisher Scientific, and the operating margin 38.6% and 17.9%. Revenue was $412M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.